Europe Point Of Care TB And Drug-resistant TB Testing Market To Reach $161.05 Million By 2030

Europe Point Of Care TB And Drug-resistant TB Testing Market Growth & Trends

The Europe point of care TB and drug-resistant TB testing market size is expected to reach USD 161.05 million by 2030 and is projected to grow at a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by several factors, notably the high prevalence of tuberculosis (TB) and increasing cases of drug-resistant strains. Despite a 25% reduction in TB deaths by 2022, as reported by the Global Tuberculosis Report, progress was significantly impacted by COVID-19. The WHO European Region saw a gain reversal due to pandemic-related disruptions, with TB incidence rates remaining above pre-pandemic levels in 2022. This ongoing challenge underscores the need for practical, rapid diagnostic solutions to manage TB and DR-TB effectively.

Government and regulatory support further drive the market’s expansion. The European Union’s strategic initiatives, such as the Action Plan on Antimicrobial Resistance (AMR) and the WHO’s Regional Platform to End TB in Eastern Europe, emphasize the importance of enhancing diagnostic capabilities and treatment strategies for TB and drug-resistant strains. These initiatives aim to address the setbacks caused by COVID-19 and improve TB outcomes through increased investment in point of care (PoC) technologies. Additionally, the certification of advanced diagnostic tools like QuantiFERON-TB Gold Plus under the EU’s new In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746 highlights the regulatory push for higher standards in TB diagnostics, contributing to market growth.

Technological advancements play a crucial role in market expansion. Recent developments in molecular diagnostics, including rapid PCR assays and next-generation sequencing (NGS), have significantly improved the accuracy and speed of TB detection. These innovations enable high-throughput testing and precise identification of drug-resistant strains, addressing the urgent need for timely diagnosis and treatment.

 Request a free sample copy or view report summary: Europe Point Of Care TB And Drug-resistant TB Testing Market Report

Europe Point Of Care TB And Drug-resistant TB Testing Market Report Highlights

• Based on test, the immunoassays segment dominated the market with a substantial share of 34.9% in 2023, due to its rapid results and ease of use.

• In 2023, the clinics and hospitals segment dominated the market with the largest share of 48.1%.

• Clinics and hospitals are primary settings for TB diagnosis and management due to their capacity to offer comprehensive diagnostic and treatment services.

Europe Point Of Care TB And Drug-resistant TB Testing Market Segmentation

Grand View Research has segmented the Europe PoC TB and drug-resistant TB testing market based on test, end use, and country:

Europe PoC TB And Drug-resistant TB Testing Test Outlook (Revenue, USD Million, 2018 - 2030)

• Molecular Diagnostics

• Immunoassays

• Culture-based Tests

• Serological Tests

• Others

Europe PoC TB And Drug-resistant TB Testing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Clinics and Hospitals

• Diagnostic Laboratories

• Others

Europe PoC TB And Drug-resistant TB Testing Regional Outlook (Revenue, USD Million, 2018-2030)

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Russia

  • Armenia

  • Azerbaijan

  • Belarus

  • Kazakhstan

  • Rest of Europe

List of Key Players in the Europe Point Of Care (PoC) TB And Drug-resistant TB Testing Market

• Cepheid (Danaher Corporation)

• Molbio Diagnostics

• Abbott Laboratories

• BD (Becton, Dickinson and Company)

• Roche Diagnostics

• Qiagen

• Lucira Health

• BioMérieux

• Thermo Fisher Scientific

• Fujifilm (Fujifilm Healthcare)

• MedMira

• SD Biosensor

• Trivitron Healthcare